Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $149 |
| Triangulated Fair Value | $120 |
| 12-mo Scenario PWEV | $141 |
| Implied Return | -19% |
| Forward P/E | 6.3x |
| Market Cap | $9B |
| 52-Week Range | $140 – $246 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Re-Rate / Deleveraging' (8% weight) — targets $250, +68% vs spot. It needs Gross Margin to surprise to the upside.
The dashboard below is the whole argument on one page: spot ($149) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Reimbursement Cuts / Labor Inflation' (20%) — targets $62, -58% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
Gross Margin explains 65% of Monte Carlo outcome variance — the single variable that decides which side is right.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q1): management +0.13 vs analyst floor +0.00 → delta +0.13 (n=26 mgmt / 22 Q&A; 4th pctile across the S&P book, z -1.6).
Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q1 | +0.13 | +0.00 | +0.13 |
| 2025Q4 | +0.37 | +0.13 | +0.24 |
| 2025Q3 | +0.37 | +0.25 | +0.12 |
| 2025Q2 | +0.29 | +0.20 | +0.08 |
News (last 365d, 1000 articles): avg ticker sentiment +0.26 (bullish 50% / bearish 3%)
Scenario Analysis
The tree runs from a structural 'Structural — Reimbursement Cuts / Labor Inflation' downside ($62) to a 'Bull — Re-Rate / Deleveraging' bull case ($250); the probability-weighted blend (PWEV $141) is -5% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Reimbursement Cuts / Labor Inflation | 20% | $62 | -58% |
| Volume / Payer-Mix Recession | 17% | $105 | -29% |
| Base — Admissions + Pricing | 35% | $147 | -1% |
| Growth — Volume Recovery / Service-Line | 20% | $198 | +33% |
| Bull — Re-Rate / Deleveraging | 8% | $250 | +68% |
| Probability-Weighted (PWEV) | — | $141 | -5% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Reimbursement Cuts / Labor Inflation (20%, $62). Structural impairment — reimbursement cuts / labor inflation: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 62.12; probability: 0.2.
- Volume / Payer-Mix Recession (17%, $105). Cyclical downturn — patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage weakens for 1–2 years before normalising. Drivers — implied_target: 105.49; probability: 0.17.
- Base — Admissions + Pricing (35%, $147). Mid-cycle — normalised patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage; disciplined capital allocation; steady returns. Drivers — implied_target: 146.51; probability: 0.35.
- Growth — Volume Recovery / Service-Line (20%, $198). Upside — volume recovery + deleveraging lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 197.79; probability: 0.2.
- Bull — Re-Rate / Deleveraging (8%, $250). Upside tail — sustained tight conditions or a structural re-rate on volume recovery + deleveraging. Drivers — implied_target: 249.81; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $124 | -17% |
| Peer P/E re-rate | multiple | $409 | +175% |
| Peer EV/Revenue re-rate | multiple | $650 | +337% |
| Scenario PWEV | multiple | $141 | -5% |
| DCF (5-year + terminal) | cash flow + terminal × | $104 | -30% |
| Triangulated (weighted) | — | $120 | -19% |
peer P/E re-rate excluded from the weighted blend — diverges >55% from the Monte-Carlo / scenario core. For a high-leverage equity the per-share DCF (enterprise value less large net debt) is hypersensitive to the terminal multiple; a peer re-rate across heterogeneous margins is apples-to-oranges. Shown above for reference; the blend leans on the multiple-discipline and scenario anchors.
Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $124 + scenario PWEV $141, ≈ spot); the weighted blend $120 (-19%) sits below it because the cash-flow DCF ($104) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $124 and 38% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (65% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 9.0%, 5x terminal FCF multiple → $104. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 17.385x) implies $409. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is wide (genuine disagreement — low valuation confidence).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Hospital / Dialysis Operations | $17.8B | 100% | 4% | 10% | 6x | 7% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage |
| net_debt_or_cash_b | -5.01 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.07 |
| div_yield | 0.0055 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | reimbursement cuts / labor inflation |
| upside | volume recovery + deleveraging |
Industry Context — Health Payers Providers
This name sits in the Health Payers Providers as a providers. patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: UNH (managed_care) · CVS (managed_care) · HCA (providers) · ELV (managed_care) · CI (managed_care) · HUM (managed_care) · CNC (managed_care) · DVA (providers) · UHS (providers)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Cost-Trend Spike / Reimbursement-Reform Squeeze | 37% | 37% | |
| Mid-Cycle — Membership & Volume Growth | 35% | 35% | |
| Upside — Margin Recovery / Care-Services | 28% | 28% |
On the cluster's key downside — Cost-Trend Spike / Reimbursement-Reform Squeeze () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_payers_providers cycle is the shared macro driver. Driver — medical-cost trend (MLR) + utilization + reimbursement/regulation Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $18B | $2B | $1B | $1B | $1B | $1B |
| FY+2 | $19B | $2B | $1B | $1B | $2B | $1B |
| FY+3 | $20B | $2B | $1B | $1B | $2B | $1B |
| FY+4 | $20B | $2B | $1B | $1B | $2B | $1B |
| FY+5 | $21B | $2B | $1B | $1B | $2B | $1B |
| Terminal | — | — | — | — | $2B × 5x | $5B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 7% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 9.0% · Σ PV(FCF) $6B + PV(terminal) $5B = EV $11B; + net cash → equity $6B ÷ diluted shares 0.06B = $104/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $292/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 4% vs WACC 9% → below WACC — the incremental build is value-dilutive.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| HCA | 1.764x | 12.76x | 4% | 15% |
| TECH | 9.21x | 34.6x | 6% | 25% |
| HSIC | 0.982x | 15.65x | 5% | 6% |
| CRL | 3.256x | 19.12x | 6% | 16% |
| Median | 2.51x | 17.385x | — | — |
Peer-median fwd P/E → $409; EV/Rev → $650.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $104 | 47% | $48 |
| Scenario PWEV | $141 | 33% | $47 |
| Monte Carlo median | $124 | 20% | $25 |
| Triangulated | — | 100% | $120 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 3.5x | 4.2x | 5.0x | 5.8x | 6.5x |
|---|---|---|---|---|---|
| 7% | $89 | $102 | $118 | $133 | $146 |
| 8% | $83 | $96 | $111 | $125 | $138 |
| 9% | $78 | $90 | $104 | $118 | $130 |
| 10% | $72 | $84 | $97 | $111 | $122 |
| 11% | $67 | $78 | $91 | $104 | $115 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $43 | $67 | $91 | $115 | $139 |
| -1.5pp | $46 | $72 | $97 | $123 | $148 |
| +0.0pp | $50 | $77 | $104 | $131 | $158 |
| +1.5pp | $53 | $82 | $110 | $139 | $168 |
| +3.0pp | $57 | $87 | $117 | $148 | $178 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $50 | $158 | $108 |
| Terminal × ±15% | $91 | $117 | $26 |
| Revenue CAGR ±3pp | $91 | $117 | $26 |
| WACC ±1pp | $97 | $111 | $13 |
| FCF conversion ±10% | $104 | $104 | $0 |
Company lever — SoP/share vs Hospital / Dialysis Operations multiple (AI re-rating) (base 6x)
| Multiple | 4.2x | 5.1x | 6.0x | 6.9x | 7.8x |
|---|---|---|---|---|---|
| SoP/share | $1,143 | $1,406 | $1,669 | $1,931 | $2,194 |
Load-Bearing Assumptions
DCF: WACC 9%, terminal multiple 5×, FY+5 revenue $21B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
A miss on Gross Margin drops the case toward the structural target $62.
Fact / Inference / Speculation
- FACT: Spot $149; 52-week range $140–$246; engine rating HOLD; base-case target $141 (-5%).
- INFERENCE: Triangulated FV $120 (-19%). Gross Margin explains 65% of Monte Carlo outcome variance — the single variable that decides which side is right.
- SPECULATION: At current prices the embedded bet is that Gross Margin surprises to the upside — Gross Margin carries 65% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $154 (+4% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin (65% of variance) — a fundamental call. SBC runs —M TTM (disclosed in the appendix).